Navigation Links
NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
Date:3/26/2008

Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis. The research, to be published in the April 2008 issue of Experimental Biology and Medicine, provides new insights for the understanding of the anti-cancer effects of NSAIDs.

NSAIDs have been used for the suppression of pain and inflammation in the clinic for many years. The main targets of these drugs are cyclooxygenases (COXs) which play critical roles in maintaining physiological homeostasis, mediating inflammatory reactions and promoting tumorigenesis. However, COX-independent effects are also important for the inhibition of cancer development by NSAIDs. Indeed, NSAIDs are considered as a novel class of effective chemopreventive drugs.

The research team, led by Wen-Chun Hung, Dean of College of Science, National Sun Yat-Sen University, and a recent doctorial graduate Mei-Ren Pan and two collaborators Hui-Chiu Chang and Lea-Yea Chuang of Kaohsiung Medical University found that NSAIDs up-regulated several anti-metastatic genes including secreted protein acidic and rich in cysteine (SPARC), thrombospindin-1 (TSP-1), TSP-3 and tissue inhibitors of metalloproteinase-2 (TIMP-2) in human lung cancer cells. Our functional assay suggested that increases of SPARC and other anti-metastatic genes were important for NSAIDs to inhibit tumor invasion and metastasis said Wen-Chun Hung. More importantly, we elucidated the underlying mechanism and demonstrated that up-regulation of SPARC in human lung cancer cells was mediated via inhibition of DNA methyltransferases (DNMTs) expression and promoter de-methylation. This is the first report to show that NSAIDs may inhibit the expression of DNMTs to reverse promoter methylation and to reactivate gene transcription.

The researchers say that hypermethylation of tumor suppressor genes is frequently found in many types of human cancer and is a crucial step for tumorigenesis. Recently, a number of de-methylating agents have been reported to exhibit potent anti-cancer effects in vitro and in vivo. Therefore, these agents are considered to be useful for cancer therapy. As a matter of fact, two de-methylating drugs 5-Azacitidine and 5-Aza-2-deoxycytidine (decitabine) have been approved for the treatment of myelodysplastic syndromes, a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology. Hung says our results indicate that NSAIDs may function as de-methylating agents via inhibition of DNMTs and may provide a new strategy for the treatment or prevention of cancer. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees and said These unique findings by Dr. Hung and colleagues suggest an entirely new function for non-steroidal anti-inflamatory drugs in cancer therapy. This is an exciting advance for the field of Cancer biology.


'/>"/>

Contact: Dr. Wen-Chung Hung
hung1228@ms10.hinet.net
886-752-52000 x5817
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
2. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
3. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
4. Overweight Hispanic children shown to have vascular inflammation
5. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
6. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
7. Cell-death receptor links cancer susceptibility and inflammation
8. iNOS expression may links chronic biliary inflammation to malignant transformation
9. Diabetes Linked to Blood Vessel Inflammation
10. Low-carb diet reduces inflammation and blood saturated fat in metabolic syndrome
11. Researchers develop powerful tool to study the genetics of inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology: